Ms. Manhard has served as a member of our Board since June 2020. Ms. Manhard is a biopharmaceutical executive with more than 25 years of drug development, regulatory affairs, quality assurance, pharmacovigilance and pharmaceutical operations experience.
Ms. Manhard has served as the Chief Development Officer at Connect Biopharma since September 2024. Prior to Connect Biopharma, Ms. Manhard served as the Senior Vice President of Global Strategic Planning and Execution for Acadia Pharmaceuticals Inc. and prior to Acadia, Ms. Manhard served as the Executive Vice President, Drug Development of Heron Therapeutics, Inc., where she was instrumental in the development, registration and commercial support of SUSTOL®, CINVANTI®, ZYNRELEF® and APONVIE®. Prior to Heron, Ms. Manhard served as Senior Vice President of Regulatory Affairs and Development Operations at Ardea Biosciences, Inc., a wholly-owned subsidiary of AstraZeneca PLC, where she led the US, EU and rest of world registration activities for Zurampic® and also oversaw general corporate operations and anti-viral and oncology drug development since joining Ardea. Previously, Ms. Manhard was President of her own consultancy firm, was Vice President of Regulatory Affairs for Exelixis, Inc., and held multiple regulatory positions at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company, supporting development of anticancer and antiviral products, including Viracept®. Ms. Manhard was also previously with Bristol-Myers Squibb Company in regulatory affairs, responsible for oncology compounds, including Taxol®, and infectious disease compounds, including Videx® and Zerit®. Ms. Manhard began her industry career in clinical research with Eli Lilly and Company and G.H. Besselaar Associates (Covance Inc.).
Ms. Manhard currently serves as a member of the board of directors of Toragen, Inc. and Shoreline Biosciences and previously served as a member of the board of directors of Heron Therapeutics, Inc. Ms. Manhard is a member of the Fleet Science Center board of trustees and the University of Florida College of Liberal Arts & Sciences Dean’s Leadership Council. She received a B.S. degree in zoology and a B.A. degree in French from the University of Florida.
What is Kimberly Manhard's net worth?
The estimated net worth of Kimberly Manhard is at least $1.06 million as of September 8th, 2026. Ms. Manhard owns 9,500 shares of Inhibrx Biosciences stock worth more than $1,058,490 as of September 11th. This net worth estimate does not reflect any other assets that Ms. Manhard may own. Learn More about Kimberly Manhard's net worth.
How do I contact Kimberly Manhard?
Has Kimberly Manhard been buying or selling shares of Inhibrx Biosciences?
In the last ninety days, Kimberly Manhard has sold $57,570.00 in shares of Inhibrx Biosciences stock. Most recently, Kimberly Manhard sold 500 shares of the business's stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $115.14, for a transaction totalling $57,570.00. Following the completion of the sale, the director now directly owns 9,500 shares of the company's stock, valued at $1,093,830. Learn More on Kimberly Manhard's trading history.
Who are Inhibrx Biosciences' active insiders?
Are insiders buying or selling shares of Inhibrx Biosciences?
During the last twelve months, Inhibrx Biosciences insiders bought shares 3 times. They purchased a total of 32,500 shares worth more than $3,499,725.00. During the last twelve months, insiders at the sold shares 2 times. They sold a total of 350,500 shares worth more than $11,345,070.00. The most recent insider tranaction occured on September, 8th when Director
Douglas Forsyth bought 2,500 shares worth more than $286,625.00. Insiders at Inhibrx Biosciences own 18.3% of the company.
Learn More about insider trades at Inhibrx Biosciences. Information on this page was last updated on 9/8/2026.
